# CSF1R-IN-21

| | |
|---|---|
| **Cat. No.:** | HY-157996 |
| **CAS No.:** | 2935479-62-0 |
| **Molecular Formula:** | $C_{24}H_{20}F_3N_5O_3$ |
| **Molecular Weight:** | 483.44 |
| **Target:** | c-Fms |
| **Pathway:** | Protein Tyrosine Kinase/RTK |
| **Storage:** | Please store the product under the recommended conditions in the Certificate of Analysis. |



## BIOLOGICAL ACTIVITY

| | |
|---|---|
| **Description** | CSF1R-IN-21 (compound 7e) is a CSF-1R Inhibitor with an $IC_{50}$ value of 31 nM. CSF1R-IN-21 inhibits CSF-1R auto-phosphorylation and can be used for the research of neurodegenerative diseases [1]. |
| **$IC_{50}$ & Target** | CSF-1R<br>31 nM ($IC_{50}$) |
| **In Vitro** | CSF1R-IN-21 (compound 7e) (10 μM, 6 h) inhibits CSF-1R auto-phosphorylation and exhibits low cytotoxicity in cell viability assays of EOC20 cell line[1].<br>CSF1R-IN-21 (compound 7e) (50 μM, 4 h) shows well blood-brain barrier permeability in the parallel artificial membrane permeability test (PAMPA)[1].<br>CSF1R-IN-21 (compound 7e) (10 M, 0/30/120 min) performs well in the plasma stability test[1].<br>CSF1R-IN-21 (compound 7e) (1 mM, 30 min) shows moderate stability in the microsomal stability test[1].<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

Cell Viability Assay[1]

| | |
|---|---|
| Cell Line: | RAW264.7, EOC 20 |
| Concentration: | 10 μM |
| Incubation Time: | 6 h |
| Result: | Showed a very low cytotoxic effect on microglial cell EOC 20. |

## REFERENCES

[1]. Baek J, et al. Discovery of N-(5-amido-2-methylphenyl)-5-methylisoxazole-3-carboxamide as dual CSF-1R/c-Kit Inhibitors with improved stability and BBB permeability. Eur J Med Chem. 2024 Feb 20;268:116253.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA